Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression

Bladder cancer (BC) is a heterogeneous disease with highly variable clinical and pathological features, and resulting in different outcomes. Such heterogeneity ensues from distinct pathogenetic mechanisms and may consistently affect treatment responses in single patients. Thus, over the last few yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanguedolce, Francesca, Zanelli, Magda, Palicelli, Andrea, Ascani, Stefano, Zizzo, Maurizio, Cocco, Giorgia, Björnebo, Lars, Lantz, Anna, Falagario, Ugo Giovanni, Cormio, Luigi, Carrieri, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319819/
https://www.ncbi.nlm.nih.gov/pubmed/35887164
http://dx.doi.org/10.3390/ijms23147819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319819/
https://www.ncbi.nlm.nih.gov/pubmed/35887164
http://dx.doi.org/10.3390/ijms23147819

Ejemplares similares